

1 **Title:** Leveraging of SARS-CoV-2 PCR cycle thresholds values (Ct) to forecast COVID-19 trends
2 **Authors:** Nicolas Yin¹, Simon Dellicour^{2,3}, Valery Daubie¹, Nicolas Franco^{4,5}, Magali Wautier¹, Christel
3 Faes⁵, Dieter Van Cauteren⁶, Liv Nymark^{7,8}, Niel Hens^{5,9}, Marius Gilbert², Marie Hallin^{1,10,#}, Olivier
4 Vandenberg^{10,11,12,#}

5 [#]These authors contributed equally to this work as co-senior authors.

6 **Affiliations**

- 7 1. Department of Microbiology, Laboratoire Hospitalier Universtaire de Bruxelles – Universitair
8 Laboratorium Brussel (LHUB-ULB), Université Libre de Bruxelles (ULB), Brussels, Belgium.
- 9 2. Spatial Epidemiology Lab (SpELL), Université Libre de Bruxelles, Bruxelles, Belgium
- 10 3. Department of Microbiology, Immunology and Transplantation, Division of Clinical and
11 Epidemiological Virology, Rega Institute, KU Leuven, Leuven, Belgium
- 12 4. Namur Centre for Complex Systems (naXys) & Department of Mathematics, University of
13 Namur, Namur, Belgium
- 14 5. Interuniversity Institute for Biostatistics and statistical Bioinformatics (I-BioStat), Data Science
15 Institute, Hasselt University (UHasselt), Hasselt, Belgium
- 16 6. Scientific Directorate of Epidemiology and public health, Sciensano, Brussels, Belgium
- 17 7. Norwegian Institute of Public Health, Division of Infection Control and Environmental Health,
18 Oslo, Norway
- 19 8. Department of Health Management and Health Economics, University of Oslo, Oslo, Norway
- 20 9. Centre for Health Economic Research and Modelling Infectious Diseases, Vaccine and
21 Infectious Disease Institute, University of Antwerp, Antwerp, Belgium
- 22 10. Centre for Environmental Health and Occupational Health, School of Public Health, Université
23 Libre de Bruxelles (ULB), Brussels, Belgium

24 11. Clinical Research and Innovation Unit, Laboratoire Hospitalier Universitaire de Bruxelles -
25 Universitair Laboratorium Brussel (LHUB-ULB), Université Libre de Bruxelles (ULB), Brussels,
26 Belgium.

27 12. Division of Infection and Immunity, Faculty of Medical Sciences, University College London,
28 London, United Kingdom

29 **Corresponding author:** Nicolas Yin

30 **Corresponding author email:** nicolas.yin@lhub-ulb.be

31 **Abstract**

32 **Introduction:** We assessed the usefulness of SARS-CoV-2 RT-PCR cycle thresholds (Ct) values trends
33 produced by the LHUB-ULB (a consolidated microbiology laboratory located in Brussels, Belgium) for
34 monitoring the epidemic's dynamics at local and national levels and for improving forecasting
35 models.

36 **Methods:** SARS-CoV-2 RT-PCR Ct values produced from April 1, 2020, to May 15, 2021, were
37 compared with national COVID-19 confirmed cases notifications according to their geographical and
38 time distribution. These Ct values were evaluated against both a phase diagram predicting the
39 number of COVID-19 patients requiring intensive care and an age-structured model estimating
40 COVID-19 prevalence in Belgium.

41 **Results:** Over 155,811 RT-PCR performed, 12,799 were positive and 7,910 Ct values were available
42 for analysis. The 14-day median Ct values were negatively correlated with the 14-day mean daily
43 positive tests with a lag of 17 days. In addition, the 14-day mean daily positive tests in LHUB-ULB
44 were strongly correlated with the 14-day mean confirmed cases in the Brussels-Capital and in
45 Belgium with coinciding start, peak and end of the different waves of the epidemic. Ct values
46 decreased concurrently with the forecasted phase-shifts of the diagram. Similarly, the evolution of

47 14-day median Ct values was negatively correlated with daily estimated prevalence for all age-
48 classes.

49 **Conclusion:** We provide preliminary evidence that trends of Ct values can help to both follow and
50 predict the epidemic's trajectory at local and national levels, underlining that consolidated
51 microbiology laboratories can act as epidemic sensors as they gather data that are representative of
52 the geographical area they serve.

53 **Keywords:** COVID-19, SARS-CoV-2, forecast, epidemic trend, Ct values

54 **Conflict of interest:** none

55 **Funding statement:** The authors received no financial support for this research

56 Leveraging of SARS-CoV-2 PCR cycle thresholds values (Ct) to forecast COVID-

57 19 trends

58 Introduction

59 The coronavirus disease 2019 (COVID-19) pandemic dramatically highlighted the central position of
60 diagnostic testing, not only for the clinical management of infected individuals but also for
61 surveillance purposes¹. The use of clinical microbiology laboratories (CMLs) data to survey the
62 presence of specific microorganisms in a given population represents one of the most established
63 public health surveillance tools of infectious diseases. In a previous study, we proved that influenza
64 trends in Belgium may be estimated using laboratory data provided by a CML serving the wider
65 Brussels-Capital Region area². Since the start of the COVID-19 pandemic, several authors have
66 demonstrated that CMLs could represent the first step toward a global set of sensor networks for
67 infectious diseases surveillance, where each one of the CMLs can be seen as a real-time sensor in its
68 area within an interconnected, complex network^{1,3,4}. In this perspective, CMLs have become a
69 cornerstone in the fight against SARS-CoV-2 infections due to their ability to process large amounts of
70 samples in large geographic areas while using highly specialized diagnostic tests^{1,5}.

71 By reporting to Sciensano, the Belgian national public health research institute, the number of new
72 positives among the tests conducted each day, CMLs share the data needed to estimate the effective
73 reproduction number (R_t)^{6,7}. However, the data represent the growth rate of positive tests and not
74 the incidence of infection, which requires adjustments to account for changes in testing capacity,
75 delay between infection and test report date, and conversion from prevalence to incidence. We
76 previously showed that SARS-CoV-2 RT-PCR cycle threshold (Ct) values are different between
77 populations, with lower Ct values – thus higher viral loads – for outpatients, likely to be recently
78 infected and higher Ct values for inpatients⁸. In a recent article, Hay *et al.* used the SARS-CoV-2 RT-
79 PCR Ct values in a model to forecast epidemic's trajectory⁹. At the time of writing, RT-PCR assays are

80 not standardised and the Ct values obtained using various PCR methods on various instruments in
81 various laboratories using various sampling methods cannot be easily aggregated by surveillance
82 systems. Sciensano recently encouraged laboratories to report their results using a semi-quantitative
83 approach where a viral load below 10^3 RNA copies/mL is considered as “weak positive”¹⁰.
84 Sciensano’s primary goal was to approach the actual infectiousness of patients with persistent
85 positive RT-PCR. Therefore, the semi-quantitative dimension of positive test results is not used by
86 surveillance systems yet.

87 Besides the difficulty of making use of all the data provided by CMLs in real time, public health
88 authorities also face the challenge of making decisions, as the constantly evolving situation requires
89 permanent adaptation¹¹. In this perspective, various predictive models have been developed to
90 support policy makers¹²⁻¹⁵. To improve and facilitate the decision-making process, Hens *et al.*
91 developed a phase portrait to monitor the epidemic allowing a real-time assessment of whether
92 intervention measures are needed to keep hospital capacity under control¹⁶. Nevertheless, such
93 supportive decision tools are often designed at the national level instead of the hospital level where,
94 during the pandemic, hospital managers needed support to forecast the cancellation and
95 reintroduction of a series of medical activities, such as the surgical care program, or the number of
96 COVID-related ICU beds¹⁷. Thanks to the huge amount of data they collect on a daily basis, CMLs
97 could also help the hospital structures they serve to anticipate the evolution of the epidemic and
98 forecast their hospitalisation and medical activities.

99 The objectives of this study were: (1) to verify the accuracy of using of SARS-CoV-2 PCR Ct values
100 trends in a single CML to monitor the dynamics of the epidemic; (2) to determine the added-value of
101 using these data as an additional advanced information for scenario analysis, in relation to a phase
102 diagram and an age-structured compartmental model, both developed to follow the path of the
103 Belgian COVID-19 epidemic^{14,15}.

104

105 **Methods**

106 The “Laboratoire Hospitalier Universitaire de Bruxelles - Universitair Laboratorium Brussel” (LHUB-
107 ULB) is a merged clinical laboratory serving five university hospitals located in the Brussels-Capital
108 region in Belgium⁸. All the SARS-CoV-2 PCR results produced between April 1, 2020, and May 15,
109 2021, by the LHUB-ULB were extracted anonymously from its laboratory information system. The
110 data collected were patients’ postal code, age, qualitative PCR results, Ct values, instruments on
111 which PCR were performed, and sampling dates. National Belgian data were extracted from the
112 “total number of tests by date” and the “confirmed cases by date, province, age and sex” public
113 dataset available on the Sciensano website on May 27, 2021. These datasets contain the total
114 number of tests, the number of positive tests per day, and the confirmed number of cases per day
115 and province. To analyse trends and minimize day-to-day and holiday-related fluctuations, we
116 computed mean daily positive tests and cases, and median and mean Ct values from May 1, 2020 to
117 May 15, 2021, using a backward sliding window of 14 days (hereafter referred as “14-day mean
118 positive tests/cases” and “14-day median/mean Ct values”).

119 To follow the trends of Ct values variation during the study period, only the SARS-CoV-2 PCR results
120 on nasopharyngeal swabs (NPS) obtained using the *m2000 RealTime SARS-CoV-2* assay (Abbott
121 Molecular, USA) were considered, this assay being the only one used by our laboratory during the
122 entire period of interest. As detection of both targeted genes (RdRp and N) was performed using the
123 same fluorophore, the Ct values of this assay were observed up to 32 cycles and were not
124 comparable with Ct values of other RT-PCR assays. Ct values were plotted against a standard
125 calibration curve provided by the Belgian NRC to obtain the semi-quantitative results recommended
126 by Sciensano¹⁰. Accordingly, results with a Ct > 22.3 were considered as “weak positive” (viral load <
127 10³ RNA copies/mL). Correlations between 14-day median/mean Ct values and daily mean positive
128 tests were calculated using Spearman’s r_s rank correlation coefficient. This correlation was performed
129 with shifts of 0 to 30 days in the median and mean Ct values, to determine the shift with the highest

130 r_s between the daily mean number of positive tests and Ct values. To test their validity as a source for
131 COVID-19 surveillance, LHUB-UB's data were also compared with all COVID-19 confirmed case
132 notifications according to geographical coverage and time distribution.

133 We used phase diagrams depicting the evolution of COVID-19 hospitalisations in Belgium to compare
134 these trends with the evolution of Ct values measures through time¹⁶. These diagrams were
135 developed to predict the number of COVID-19 patients requiring intensive care by considering the 7-
136 day mean new hospitalisations and the daily ratio of the past 14-day new hospitalisations. For each
137 combination, the total number of hospitalisations is projected for a horizon of 14 days, from which
138 the number of patients requiring intensive care is predicted based on the distribution of the time
139 spent in an intensive care unit (ICU). The hospital contingency plan in Belgium consists of five
140 different phases (phases 0, 1A and 1B, 2A and 2B), incrementing COVID-19 related ICU beds
141 capacities. Within this scheme, the total number of patients in ICU moves from 2001 to 2821,
142 consequently yielding a gradual decrease in non-COVID-19 ICU capacity¹⁶. The hospital and future
143 COVID-related ICU load is thus depicted from green to red: the green region can be considered a
144 "safe zone" in which the number of new hospitalisations is limited with a decrease (growth < 1) or a
145 limited increase (growth > 1) and associated with a limited number of COVID-19 patients at ICU (first
146 part of Phase 0); the yellow region, a region of increased vigilance (second part of Phase 0). The
147 orange (Phases 1A & 1B) and red (Phases 2A & 2B) regions are "high impact" and "no-go" zones, in
148 which non-COVID-19 care decreases substantially and additional capacity for COVID-19 needs to be
149 provided for.

150 A comparison between the evolution of 14-day median Ct values by age classes and the daily
151 estimated Belgian COVID-19 prevalence for these age classes has been performed using a model of
152 deterministic continuous age-structured compartmental model (extended SEIR-type) integrating
153 social contact data and calibrated on hospitalisations and deaths incidence data as well as serological
154 studies¹⁵. The prevalence was estimated for the following age classes in years: 0-24, 25-44, 45-64,


155 65-74 and 75+ as the proportion of the sum of the infected compartments (exposed, asymptomatic,
156 presymptomatic, symptomatic and hospitalised individuals) compared to the total size of the age
157 class, with a 90% confidence interval estimated by Bayesian analysis. This method aims to provide a
158 reliable comparison with the spreading of COVID-19 in Belgium among age classes since the number
159 of RT-PCR positive tests are known to be biased over time due to testing policy changes, especially
160 regarding the youngest and oldest classes.

161 Data from all sources were collected retrospectively and anonymously before analysis from a routine
162 surveillance perspective. Ethics approval was granted by the Ethics Committee of the Saint-Pierre
163 University Hospital. No written informed consent was collected.

164

165 Results

166 From April 1, 2020, to May 15, 2021, a total of 155,049 SARS-CoV-2 RT-PCR were performed in the
167 LHUB-ULB and resulted in 12,771 positive results of which 7,906 Cts were analysed. A peak of LHUB-
168 ULB 14-day mean daily positive tests was reached during the Belgian second wave on October 28,
169 2020 ($n = 153.6$, Fig. 1). Beforehand, a lower peak was reached during the summer on August 22,
170 2020 ($n = 24.4$). In both cases, these peaks were preceded by a drastic decrease in the 14-day median
171 Ct values reaching local minima respectively 16 days before (13.12 on October 12, 2020) and 12 days
172 before (12.76 on August 10, 2020). Ct values were negatively correlated with the number of LHUB-
173 ULB positive tests, with a maximum reached for the correlation between the 14-day median Ct values
174 with a lag of 17 days and the 14-day mean positive tests ($r_s = -0.836$), as well as between the 14-day
175 mean Ct values with a lag of 19 days and the 14-day mean positive tests ($r_s = -0.834$).




177 **Figure 1. COVID-19 trends in a laboratory perspective: evolution of the 14-day median (solid red curve) and**
178 **mean (dashed red curve) Ct values obtained from April 1, 2020, to May 15, 2021 (LHUB-ULB, Brussels Region,**
179 **Belgium).** Reddish areas surrounding the solid red curve indicate the 95% confidence interval (CI) associated with
180 median Ct values, and the thinner red dashed lines indicate the 95% CI associated with mean Ct values. The
181 horizontal dashed line refers to the threshold value of 22.3. Those curves are superimposed on the evolution of

182 the number of COVID-19 positive cases identified at the LHUB-ULB. As detailed in the text, median and mean Ct
183 values, as well as COVID-19 positive cases, were all computed using a backward 14-day sliding window. In the
184 embedded box, we report the relationship between (i) the Spearman correlation between daily estimates of
185 median (solid curve) and mean (dashed curve) Ct values and the number of COVID-19 positive cases (LHUB-ULB)
186 and (ii) the time gap considered between the Ct measures and the number of positive cases. On top of the graph,
187 we also report key dates of the Belgian epidemic.

188 During the same period, a total of 1,381,393 tests were performed across the Brussels Region and
189 13,219,135 tests across the whole of Belgian territory, of which respectively 142,562 and 1,131,719
190 tests were positive. Overall, LHUB-ULB performed respectively 8.96% (12,771/142,562) and 1.13%
191 (12,771/1,131,719) of all positive tests reported in the Brussels Region and at the national level.

192 Figure 2 shows the geographical distribution by postal code of the confirmed COVID-19 cases notified
193 by the LHUB-ULB to Sciensano and the LHUB-ULB's representativeness in the COVID-19 notification.
194 Beside the Brussels-Capital Region, which concentrated most of the tests produced by the LHUB-ULB,
195 its service area extended to several municipalities in Walloon and Flemish Region with, for some of
196 them, about 5% of all notifications. Overall, the number of positive tests produced by the LHUB-ULB
197 showed a high correlation with the regional and national trends of the incidence of COVID-19
198 notifications with coinciding start, peak and end of the different waves of the epidemic. The 14-day
199 average number of positive tests in LHUB-ULB were strongly correlated with the 14-day average
200 number of positive tests in the Brussels-Capital Region ($r_s = 0.843$) and in Belgium ($r_s = 0.810$) but
201 also with the 14-day average confirmed cases in the Brussels-Capital Region ($r_s = 0.832$) and in the
202 whole country ($r_s = 0.804$) (figure 3).




203

204

205

206

Figure 2. Mapping by municipality of SARS-CoV-2 RT-PCR tests performed by the LHUB-ULB since March 8, 2020, and of the proportion of positive cases detected by the LHUB-ULB compared to the overall number of positive cases detected in those areas. The Brussels Region is highlighted by a dark grey contour.



207

208

209

Figure 3. Compared evolution of 14-day mean number of positive SARS-CoV-2 RT-PCR tests (LHUB-ULB) with Belgium (A) and Brussels (B) 14-day mean COVID-19 cases.

210

211

212

213

214

215


216

217

218

In Figure 4, the 14-days median estimates of daily Ct values are plotted in a white to blue colour scale on the phase diagram introduced above, showing how Ct values decrease when the situation worsens (and vice versa) in trends making clockwise movements. Figure 4A shows the downward trend of the end of the first epidemic wave during which the growth in new hospitalisations progressively decreased to reach below 0%, a moment at which the number of new hospitalisations started to decline: The Ct values, low at the peak, increase when the number of new hospitalisations starts to decline. In Figure 4B, an upward trend was observed, leading to a small summer wave. As soon as both growth and hospitalisations passed from the green “safe zone” to the yellow region of “increased vigilance”, the Ct values started to decrease, concurrently crossing the threshold value of


219 22.3. The opposite effect was observed when the points fell in the green region. The second wave is
220 visualised in Figure 4C, with a clear decrease and increase of the Ct values. Finally, Figure 4D
221 corresponds to the third wave, with again the same pattern observed in the evolution of Ct values.



222

223 **Figure 4: Phase diagram generated for different time periods: situation from March 1 to July 14, 2020 (A),**
224 **situation from July 14 to September 1, 2020 (B), situation from September 1, 2020, to February 1, 2021 (C),**
225 **situation from February 1 until May 15, 2021 (D).** See the text for further detail on the principle of phase
226 diagrams. Dots of the phase diagram are coloured according to 14-day median Ct values (thus computed using a
227 backward sliding window of 14 days). Triangle symbols indicate the dates when Ct values crossed down the
228 threshold value of 22.3.

229 In Figure 5, the median of daily Ct values for different age groups are compared to the daily
230 estimated prevalence of those age groups. The overall behaviour of Ct values was almost similar for
231 all age classes and was negatively correlated to the estimated prevalence.



232

233

234

235

236

237

238

239

240

Figure 5: Ct evolution by age classes with comparison to the estimated prevalence: evolution of the daily 14-day median Ct values obtained using the Abbott RealTime SARS-CoV-2 assay from April 1, 2020, to May 15, 2021 (LHUB-ULB, Brussels region, Belgium). Reddish areas surrounding solid red curves indicate the 95% confidence interval (CI) obtained by bootstrapping method associated with daily estimates of median Ct values. Those curves are superimposed on the daily prevalence of COVID-19 infected people (proportion of infected versus Belgian demographic data) as estimated by the age-structured extended SEIR-type mathematical model. Solid grey curves indicate the 95% CI obtained by Bayesian analysis.

241 Discussion

242 Estimating the likely number of infected patients during epidemics but also the dynamics of
243 spreading in the population is crucial to carry out adequate testing and infection control measures.
244 As large and accurate data providers, CMLs can adequately support hospital capacity planning by
245 providing valuable real-time information about the incidence trends of the pandemic. This was
246 already established by a previous study on influenza ², but seems to be even more relevant in the
247 context of a more severe disease like COVID-19, where hospital capacities are crucially challenged.
248 Indeed, LHUB-ULB processed on its own 8.95% of the SARS-CoV-2 testing in the Brussels-Capital
249 Region and was proved here to be representative not only of the region but to a certain extent, the
250 whole country due its central geographic position in Belgium. A step further would be to capitalise on
251 the ability of these CMLs to rapidly detect and communicate abnormal events such as sudden
252 increase or emergence of variants of concern without the delay resulting from sending samples to
253 central sequencing platforms. Thanks to the expertise gained in such data integration, UK scientists
254 were able to rapidly share an early assessment of the variant Alpha's (lineage B.1.1.7) genomic
255 characteristics and associated clinical outcomes ¹⁸.

256 Complementarily, and providing an adequate standardisation under appropriate management and
257 regulatory structures, "virtual" CMLs consolidation can also adequately support ongoing COVID-19
258 surveillance by connecting some or all the produced data to national public health surveillance
259 systems. In the frame of the COVID-19 pandemic, Sciensano started to monitor on a daily basis the
260 epidemiological situation of SARS-CoV-2 in the country through multiple surveillance systems
261 including the "healthdata.be" platform aggregating all information from all CMLs located in Belgium
262 ¹⁹⁻²¹. The added value of such a combined structure was already demonstrated for monitoring viral
263 infections by the Infection Response Through Virus Genomics-ICONIC consortium in London ²².

264 Beyond the variation of the infectiousness over time, our results suggest that following the trend of
265 SARS-CoV-2 RT-PCR Ct values could predict the epidemic trends. Recently infected patients are

266 known to have higher viral load, thus higher infectiousness²³. A decrease in Ct values, linked to an
267 increase of recently infected people is likely to favour spreading, and goes hand in hand with an
268 increase in the total number of cases. By gathering enough comparable data using semi-quantitative
269 results, our Ct values based surveillance systems could approach in real time the average level of viral
270 load in the population, hence approach the current spreading of the virus before the increase of
271 cases becomes apparent, while avoiding the recurrent problem of normalization. Predicting the
272 shape and the size of the epidemic curve is not straightforward; and many parameters may influence
273 it such as seasonality, infection control measures and population immunity level, to cite a few. The
274 evolution of 14-day median Ct values was also tested against the daily estimated prevalence by age
275 classes, and Ct values were similarly negatively correlated for all age classes, even we observed a
276 shift by approximately half a month for the 75+ which might be due to intergenerational
277 transmission. However, a starting divergence was observed in May 2021, with Ct values increasing for
278 the oldest classes while remaining low for the youngest one. This was related to a period of
279 resumption of activities in Belgium such as reopening of schools, while older age-classes were
280 progressively becoming protected through the vaccination campaign. The prevalence projections
281 from the compartmental model followed the same trend. Hence, Ct values divergence by age classes
282 could be a good indicator of a divergence in transmission in these age classes.

283 Following the trend of the Ct values might have helped the decision makers as demonstrated with
284 the integration of the Ct values in a phase diagram predicting the number of COVID-19 patients
285 requiring intensive care at a national level. For instance, in March 2021, after a long period of
286 stagnation in the epidemic, the Belgian government decided to reopen close-contact professions and
287 increased the number of people authorized to gather outside, at a time when Ct values were
288 decreasing. This reopening was reversed a few weeks later due to the increase of cases underlining
289 the untimely decision. During the summer 2020, the evolution of Ct values accurately followed the
290 dynamic of the epidemic with an increase accompanying each decrease of the pressure on hospitals.
291 But the shift between the initial diagnosis, the admission, and the length of stay for COVID-19

292 inpatients makes it harder to anticipate the trends in hospitalisation between October 2020 and
293 March 2021 when the epidemic had no real break between peaks and the tension in hospital beds
294 remained stable. Only future evolution after a real epidemic reflux could confirm the added value of
295 following the Ct values to anticipate the phase shifts.

296 At the hospital level, being able to foresee epidemic dynamics could allow a greater ability to
297 anticipate measures such as pre-admission screenings, isolation, postponement of non-urgent
298 interventions, triage, and upscaling of human resources. In our study, each epidemic wave was
299 preceded by a drastic decrease of Ct values, the median crossing back the Ct = 22.3 value threshold
300 (i.e. the proportion of “weak positive” tests went below 50%), setting here an eventual easy-to-
301 evaluate parameter at the local level. This threshold value of 22.3 was clearly crossed back
302 concurrently with the passage of the number of new hospitalisations versus the new hospitalisations’
303 daily ratio from the green “safe zone” to the yellow region of “increased vigilance” in the phase
304 diagram. Even if the setting described here should likely be adjusted before being transposed to
305 other laboratories to take account of the specificity of their own patients (ratios
306 inpatients/outpatients and symptomatic/asymptomatic), repeating this exercise with their own data
307 could allow them to set up their own alarm threshold. Likewise, local and national surveillance
308 systems should track the difference in the proportion of strong versus weak positive results to model
309 the dynamics of the epidemic and thus to provide guidance for prevention measures as suggested by
310 Hay *et al* ⁹.

311 A potential weakness of our data is that a limited part of the LHUB-ULB activity relies on ambulatory
312 patients at the general practitioner level. Being able to reach this “non-hospitalised” population
313 would likely increase the sensitivity of a surveillance system to weak signals when the epidemic
314 begins in the community before affecting hospitals. However, the fact that overall behaviour of Ct
315 values was almost similar for all age classes and was negatively correlated to the estimated
316 prevalence in the compartment model indicates that our data capture the whole Belgian population

317 to a sufficient extend. One could also argue that correlation between Ct value and actual viral load
318 depends on many factors, such as sampling method, targeted genes, primers and probes, and
319 possible mutations in targeted genes²⁴. Due to the absence of standardisation between SARS-CoV-2
320 RT-PCR assays, we only analysed Ct values obtained using one RT-PCR assay performed on
321 nasopharyngeal swabs all along the studied period. We do believe that their number is sufficient to
322 neutralize the effect of measurement bias. Furthermore, it has been discussed that some variants
323 could exhibit an average higher viral load^{18,25,26} which could directly impact observed trends in the
324 overall evolution of Ct values. Nevertheless, this potentially higher viral load is likely to favour
325 infectiousness and should not introduce a bias regarding epidemic surveillance.

326 In conclusion, this study established a correlation between the trends in the SARS-CoV-2 RT-PCR Ct
327 values and the trends of the COVID-19 incidence a few days later. Following the dynamics of the
328 average viral load could add a dimension in the surveillance of respiratory infectious diseases.
329 Moreover, it underlines that the considerable amount of data daily collected by CMLs can play a key
330 role at both local level and beyond, depending on the geographical area they serve. By gathering
331 comparable laboratory data approaching the average viral load of respiratory viruses in the
332 population, surveillance systems might be able to better follow epidemic dynamics, establish forecast
333 models, capture weak signals, and thus anticipate uncontrolled spreading.

334 **Contributors**

335 NY, SD, VD, LN, MH, and OVDB designed the study. NY and SD managed the database. NY, SD, DVC,
336 VD and NF did the statistical analyses. NY, VD, MW and MH validated the laboratory analyses on
337 clinical samples. NY, SD, VD, NF, CF, MH, OVDB accessed and verified the data. NY, SD, NF, MH and
338 OVDB wrote the paper. All authors had the opportunity to discuss the results and comment on the
339 manuscript. All authors had full access to all the data in the study and had final responsibility for the
340 decision to submit for publication.

341 **Data sharing:**

342 The complete de-identified data set will be available upon request to Nicolas.yin@lhuh-ulb.be for
343 researchers whose proposed use of the data has been approved, for any purpose. If needed, requests
344 will require the ethics committee approval of the Saint-Pierre University Hospital (Brussels, Belgium).
345 Anonymized data are fully available on reasonable request from the corresponding author after
346 approval by the hospital ethics committee. Data Availability Statement. R script and related files
347 needed to run the analyses and generate Figures 1, 3, 4 and 5 presented in our study are all available
348 at https://github.com/sdellicour/Ct_measures_LHUB.

349 **Declaration of interests:**

350 All authors declare no competing interests.

351 **Acknowledgments**

352 We wish to thank the personnel of the LHUB-ULB for its daily technical assistance. The authors would
353 like to thank Dirk Thielens for his appreciable assistance. This work is dedicated to the healthcare
354 workers, the patients, and families affected by SARS-CoV-2. SD is supported by the Fonds National de
355 la Recherche Scientifique (FNRS, Belgium). NF, CF and NH acknowledge support from the European
356 Union's Horizon 2020 research and innovation program (NF, NH: grant number 682540 – TransMID
357 project; CF, NH: grant number 101003688 – EpiPose project).

358 References

- 359 1. Vandenberg, O., Martiny, D., Rochas, O., van Belkum, A. & Kozlakidis, Z. Considerations for
360 diagnostic COVID-19 tests. *Nat. Rev. Microbiol.* **19**, 171–183 (2021).
- 361 2. Van den Wijngaert, S. *et al.* Bigger and Better? Representativeness of the Influenza A Surveillance
362 Using One Consolidated Clinical Microbiology Laboratory Data Set as Compared to the Belgian
363 Sentinel Network of Laboratories. *Front. Public Health* **7**, 150 (2019).
- 364 3. Vandenberg, O. *et al.* Consolidation of Clinical Microbiology Laboratories and Introduction of
365 Transformative Technologies. *Clin. Microbiol. Rev.* **33**, (2020).
- 366 4. Albiger, B., Revez, J., Leitmeyer, K. C. & Struelens, M. J. Networking of Public Health Microbiology
367 Laboratories Bolsters Europe’s Defenses against Infectious Diseases. *Front. Public Health* **6**,
368 (2018).
- 369 5. Vandenberg, O., Kozlakidis, Z., Schrenzel, J., Struelens, M. J. & Breuer, J. Control of Infectious
370 Diseases in the Era of European Clinical Microbiology Laboratory Consolidation: New Challenges
371 and Opportunities for the Patient and for Public Health Surveillance. *Front. Med.* **5**, 15 (2018).
- 372 6. Van Oyen, H. & De Cock, J. Obligation de rapportage des résultats PCR/antigéniques et
373 sérologiques dans le cadre de la pandémie COVID-19. (2020).
- 374 7. Cori, A., Ferguson, N. M., Fraser, C. & Cauchemez, S. A New Framework and Software to Estimate
375 Time-Varying Reproduction Numbers During Epidemics. *Am. J. Epidemiol.* **178**, 1505–1512
376 (2013).
- 377 8. Yin, N. *et al.* SARS-CoV-2 Diagnostic Tests: Algorithm and Field Evaluation From the Near Patient
378 Testing to the Automated Diagnostic Platform. *Front. Med.* **8**, 650581 (2021).
- 379 9. Hay, J. A. *et al.* Estimating epidemiologic dynamics from cross-sectional viral load distributions.
380 *MedRxiv Prepr. Serv. Health Sci.* (2021) doi:10.1101/2020.10.08.20204222.
- 381 10. Risk Assessment Group. RAG Interpretation and Reporting of SARS-CoV-2 PCR Results. (2020).
- 382 11. Rasmussen, S. A. & Jamieson, D. J. Public Health Decision Making during Covid-19 — Fulfilling the
383 CDC Pledge to the American People. *N. Engl. J. Med.* **383**, 901–903 (2020).

- 384 12. Willem, L. *et al.* The impact of contact tracing and household bubbles on deconfinement
385 strategies for COVID-19. *Nat. Commun.* **12**, (2021).
- 386 13. Abrams, S. *et al.* Modelling the early phase of the Belgian COVID-19 epidemic using a stochastic
387 compartmental model and studying its implied future trajectories. *Epidemics* **35**, 100449 (2021).
- 388 14. Coletti, P. *et al.* A data-driven metapopulation model for the Belgian COVID-19 epidemic:
389 assessing the impact of lockdown and exit strategies. *BMC Infect. Dis.* **21**, (2021).
- 390 15. Franco, N. Covid-19 Belgium: Extended SEIR-QD model with nursing homes and long-term
391 scenarios-based forecasts. *medRxiv* 2020.09.07.20190108 (2020)
392 doi:10.1101/2020.09.07.20190108.
- 393 16. Hens, N., Faes, C. & Gilbert, M. On the timing of interventions to preserve hospital capacity:
394 lessons to be learned from the Belgian SARS-CoV-2 pandemic. *medRxiv* 2020.12.18.20248450
395 (2020) doi:10.1101/2020.12.18.20248450.
- 396 17. Fowler, A. J. *et al.* Resource requirements for reintroducing elective surgery during the COVID-19
397 pandemic: modelling study. *Br. J. Surg.* **108**, 97–103 (2021).
- 398 18. Frampton, D. *et al.* Genomic characteristics and clinical effect of the emergent SARS-CoV-2
399 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study.
400 *Lancet Infect. Dis.* (2021) doi:10.1016/S1473-3099(21)00170-5.
- 401 19. Muyltermans, G. *et al.* Surveillance of Infectious Diseases by the Sentinel Laboratory Network in
402 Belgium: 30 Years of Continuous Improvement. *PLOS ONE* **11**, e0160429 (2016).
- 403 20. Walckiers, D., Stroobant, A., Yourassowsky, E., Lion, J. & Cornelis, R. A sentinel network of
404 microbiological laboratories as a tool for surveillance of infectious diseases in Belgium.
405 *Epidemiol. Infect.* **106**, 297–303 (1991).
- 406 21. Weemaes, M. *et al.* Laboratory information system requirements to manage the COVID-19
407 pandemic: A report from the Belgian national reference testing center. *J. Am. Med. Inform.*
408 *Assoc.* **27**, 1293–1299 (2020).

- 409 22. Harvala, H. *et al.* Emergence of a novel subclade of influenza A(H3N2) virus in London, December
410 2016 to January 2017. *Eurosurveillance* **22**, (2017).
- 411 23. Singanayagam, A. *et al.* Duration of infectiousness and correlation with RT-PCR cycle threshold
412 values in cases of COVID-19, England, January to May 2020. *Eurosurveillance* **25**, (2020).
- 413 24. Dahdouh, E., Lázaro-Perona, F., Romero-Gómez, M. P., Mingorance, J. & García-Rodríguez, J. Ct
414 values from SARS-CoV-2 diagnostic PCR assays should not be used as direct estimates of viral
415 load. *J. Infect.* **82**, 414–451 (2021).
- 416 25. Cornelissen, L. & André, E. Understanding the drivers of transmission of SARS-CoV-2. *Lancet*
417 *Infect. Dis.* **21**, 580–581 (2021).
- 418 26. Tom, M. R. & Mina, M. J. To Interpret the SARS-CoV-2 Test, Consider the Cycle Threshold Value.
419 *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.* **71**, 2252–2254 (2020).
- 420